| INTRODUCTION
Many studies have examined risk factors for developing prostate cancer (PC), but they established few risk factors are as a significant contributor to the incidence of this disease. 1, 2 The development of highly sensitive, culture-independent methods of studying bacterial collections inside the human body has allowed the examination of the human microbiota, a possible risk factor for cancer development.
Alterations in the normal human microbiota could increase an individual's risk of developing malignancy via one of the paradigms suggested by Plottel and Blaser, 3 two of which are relevant to PC.
The first involves the inflammatory effect constituents of the microbiota have in a luminal organ leading to proliferative and tumorigenic changes, culminating in the development of malignancy.
The second paradigm is the effects of the human enteric microbiota on estrogen metabolism. This metabolic paradigm is particularly crucial because of the reported associations between estrogens alterations and PC risk. 4 We as urologists have not fully understood the exact mechanisms by which the urinary and fecal microbiota may lead to the development of PC, and the first step to understanding this microbiota-cancer interaction is to assess whether there are significant differences in the microbial profiles of men who do and do not have PC. We, therefore, prospectively tested the hypothesis that fecal and urinary microbiota are different between patients with and without PC.
2 | METHODS
| Patient recruitment
The Experimental group (n = 30) consists of patients scheduled to undergo transrectal magnetic resonance imaging (MRI) targeted prostate biopsy for clinical suspicion of PC. We based PC diagnosis on the results of the post-biopsy pathology report. Patients enrolled were white, non-Hispanic males, >18 years of age, residing in small metro and rural communities, and able to provide informed consent.
We excluded patients who received antibiotic therapy within 28 days from their prostate biopsy from the study and gave the intravenous pre-biopsy prophylactic antibiotics only after we have collected the samples. This research was done under an institutional review board approved protocol.
| Sample collection and processing
We obtained a rectal swab and first voided urine after a prostate massage before performing the biopsy. The goal of the prostate massage was to collect prostate expressed secretions that contain any resident microbial communities with the urine specimen.
| Rectal swabs collection
We gathered rectal swabs by inserting a sterile Dacron swab into the rectum (to a depth of <1 inch); the swab is then rotated for 360°while scrapping the rectal wall for no more than 10 s to avoid discomfort to the patient. Once collected, the swab tip was snapped off into a plastic tube containing 1 mL sterile saline. The tube was tightly capped and placed into refrigeration upon completion of the urological examination to store the specimen until transferred from the clinic to the research laboratory.
| Urine samples collection
We placed the first voided urine after a prostate massage in a sterile 15 mL conical tube and tightly capped it and put it into refrigeration after collection in preparation for transfer from the clinic to the research laboratory.
| Sample processing and next-generation sequencing (NGS) of bacterial phylotypes
We performed DNA extraction on frozen urine and fecal samples using the MoBio Ultraclean Soil Kit (Qiagen, Valencia, CA) using a MP FastPrep (MP Biomedicals, Solon, OH) for 40 s for rapid cell lysis. We quantified extracted DNA using High Sensitivity Qubit (Thermofisher, Carlsbad, CA) and amplified 15 ng of DNA using specific barcoded primers around the V3-V5 16S rRNA, as described previously. 5 We then sequenced the amplified samples using the 16S rRNA highthroughput next generation Illumina MiSeq (250 PE, San Diego, CA)
platform. To ensure our extraction kit and amplification kit were free of contamination; we used an empty well and no DNA sample as internal controls. These controls produced no product upon DNA gel purification and no peak upon spectrophotometer analysis. We generated a total of 52 100 366 sequence reads that were suitable for further investigation. Sequence reads were aligned using the Illinois-Mayo Taxon Operations for RNA Dataset Organization (IM_TORNADO), and paired-end reads were used for determination of Operational Taxonomical Units (OTU), as previously described.
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OTUs were clustered at 97% sequence similarity and classified using NCBI and the RDP reference databases. The OTUs were then analyzed using QIIME software for taxonomy comparison between biological samples. 7 
| Statistical analyses
After sequence processing, rarefaction analysis was performed to ensure evenness among the sequences analyzed. Samples that did not fit our minimum rarefaction level of 10 000 sequences per sample were dropped from further study resulting in the removal of 10 patients. At 10 000 sequences per sample, rarefaction curves plateaued demonstrating that sufficient sequencing was conducted to characterize bacterial communities within the samples ( Figure 1 ).
Specific tests on the remaining 30 patients included alpha-diversity, beta-diversity was accessed using both weighted and unweighted UNIFRAC values and taxonomical summary. We measured differences between sample alpha diversity by Shannon Index scores using Mann
Whitney U test, and we examined differences between individual
OTUs were by the nonparametric Kruskal-Wallis test setting our significance level of P < 0.05. Our goal was to compare urinary and fecal bacterial species between patients with PC and those without this disease.
| RESULTS
After analysis of the urinary and fecal microbiota, we found that the majority of patients with PC (n = 10/14) had similar bacterial communities within their urinary sample profile ( Figure 2 , left panel) and tended to cluster separately from patients without prostate cancer (n = 16) (P = 0.1733). We did not, however, find this same relationship with the analysis of the bacterial taxonomies identified in the fecal samples ( Figure 2 , right panel). Some patients with PC and benign histology were present in each cluster indicating that there were some shared bacterial species among our patient groups. We also analyzed how PC grade affected bacterial communities in urine samples and found that none of the patients with Gleason score of 7 (n = 3) clustered with sample from patients without PC (P value = 0.2885) ( Figure 3B ). Fecal clustering patterns were not affected by Gleason score staging ( Figures 3A and 3B ).
To determine which individual taxonomies were altered in patients with PC, we then plotted taxonomical summaries of both urinary and fecal samples in both patient groups. We found that patients with PC had a shift in taxonomical abundance in both urinary and fecal samples compared with patients without PC (Figure 4) . In urine, patients with PC exhibited an increased abundance of the bacterial species Veillonella, Streptococcus, and Bacteroides, while they had a decreased abundance of faecalibacterium, lactobaccili, and Actinetobacter. To determine if these differences were of significance between patients with and without PC we ran group differences among our two patient groups. We found that clostridium XVIII & IV, lachnospira, acetanaerobacterium, and faecalibacterium had higher abundance in the urine samples from patients with no cancer compared with patients with PC ( Table 1) .
Fecal samples from patients with PC had an increased abundance of bacteroides species but similar abundance levels of all other bacterial species that we identified. We then compared the diversity of the bacterial communities and found no significant changes between the patient groups for urinary or fecal samples ( Figure 5 ). These data components, such as dairy products 9 and red meat, 10 has been identified as a risk factor for PC in previous studies, and the microbial metabolism in the gut was shown to affect dairy products digestion.
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The gut microbiota has also been demonstrated to contribute to the generation of carcinogenic metabolites and inflammation, and thus potentially modify the association between diet and risk of developing cancer, in addition to its effect on estrogen levels as mentioned in our introduction. 12 A significant part of the hypothesis behind this study was that gastrointestinal microbiota might have a markedly different composition among individuals with PC risk. Our study did not prove this hypothesis to be true. One explanation for a possible type I error in our research is related to the "driver-passenger model." 13 The driverpassenger model suggests that a "driver" bacteria my start carcinogenesis, but they are later replaced by "passenger" bacteria that that has no association with the disease. The physiological and immunological changes that occur after the development of cancer could The prospective nature of the sample collection allowed us to move the urine and the stool samples to the lab within 24 h, and although it required a lot of effort from the study team, we feel that it increased the validity of our results. Utilizing patients undergoing MRItargeted biopsy of the prostate in our research is another strength of this study since there is a lower chance of misclassifying PC patients as having benign prostates. This study has limitations as well including the small sample size, the limited geographic location covered by the recruitment, and the homogeneity of the study population; all factors that could augment the effects of the environment on the human microbiota. However, previous studies did show a familiar pattern of fecal microbiota shared among inhabitants of sizeable geographic area (countries) not living very close to each other. 15 Another limitation of this study is that some patients with benign tissue had benign prostatic hyperplasia, and we did not control for that diagnosis in our analysis.
Also, negative controls were performed to test for contaminant bacterial DNA in extraction kits and reagents, but these samples were not sequenced. Finally, we still do not have a good explanation for the separation of the populations on PCOA of the urinary samples because there was no significant association between this separation and urine pH, antibiotic use, and Gleason score in our analysis. Many drugs and diet could have such an effect, but we did not control for these factors in our study.
| CONCLUSIONS
The urinary tract microbiota tends to be different between patients with and without PC. Further research should validate the benign versus malignant microbiota difference, and examine its utility as a variable in predicting biopsy results in patients with PC.
